CNS Pharmaceuticals (CNSP) Change in Accured Expenses (2018 - 2025)

CNS Pharmaceuticals (CNSP) has 8 years of Change in Accured Expenses data on file, last reported at $1.8 million in Q4 2025.

• Quarterly Change in Accured Expenses rose 199.04% year-over-year to $1.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.5 million (up 142.45% YoY) and the FY2025 annual result came in at $1.5 million, up 142.45% from the prior year.
• Change in Accured Expenses improved to $1.8 million in Q4 2025, from $667201.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $2.5 million in Q4 2022 to a low of -$2.6 million in Q3 2024.
• A 5-year average of $61973.2 and a median of $111303.5 in 2021 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2021 — Change in Accured Expenses surged 761.97% — and 2024, when it plunged 1432.8%.
• Tracing CNSP's Change in Accured Expenses over 5 years: stood at -$676273.0 in 2021, then surged by 466.6% to $2.5 million in 2022, then decreased by 27.18% to $1.8 million in 2023, then tumbled by 201.23% to -$1.8 million in 2024, then soared by 199.04% to $1.8 million in 2025.
• The last three Change in Accured Expenses figures came in at $1.8 million (Q4 2025), $667201.0 (Q3 2025), and -$1.3 million (Q2 2025), per Business Quant data.